AUTHORS
Olga Sineshchekova, Katja Mohrs2, Craig McCarthy3, Aneesha Doshi4, Mary Donoghue5, Jonathan Cruz6, Julian Jacinto7, Erica Pettigrew8, Aynur Hermann9, Jessica R. Kirshner10, Eric Smith, PhD11, John Lin, MD, PhD12, David J. DiLillo, PhD13, Kara Olson, MS14
AFFILIATIONS
1 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
2 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
4 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
5 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
6 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
7 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
8 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
9 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
10 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
11 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
12 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
13 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
14 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
ABSTRACT
Relapsed/refractory (RR) multiple myeloma (MM) remains an area of high unmet medical need despite major advances in T-cell–directed therapies. CAR T cells and CD3-engaging bispecific antibodies have substantially improved patient outcomes, yet many patients ultimately relapse, highlighting the need for deeper and more durable responses.
Effective T-cell activation requires both T-cell receptor/CD3-mediated activation ("signal 1") and costimulation ("signal 2"), most commonly through CD28. CAR T cells are engineered to provide both signals, whereas BCMA×CD3 bispecific antibodies, such as linvoseltamab, primarily deliver signal 1. This raises the possibility that a tumor-targeted CD28 bispecific antibody could augment BCMA×CD3-mediated antitumor activity by providing localized costimulation. GPRC5D is a clinically validated myeloma target, as demonstrated by the activity of GPRC5D-directed CD3 bispecific antibodies. Importantly, its high expression on malignant plasma cells and restricted expression in normal tissues make it an attractive target for localized CD28 costimulation. We therefore developed the GPRC5D×CD28 bispecific antibody REGN17372 and evaluated whether GPRC5D directed CD28 costimulation could enhance the antitumor activity of linvoseltamab.
In vitro, the combination of REGN17372 with linvoseltamab potently enhanced the antitumor activity of linvoseltamab against several MM cell lines and primary MM patient blasts. This was accompanied by increased T-cell activation and cytokine production, consistent with delivery of a critical costimulatory signal to CD28-expressing T cells. In multiple human MM xenograft models, REGN17372 significantly enhanced the antitumor efficacy of linvoseltamab. Similarly, in immunocompetent mice expressing human (hu)CD3, huCD28, huBCMA, and huGPRC5D, the combination was associated with potent activity against syngeneic tumors expressing huBCMA and huGPRC5D. Importantly, REGN17372 had no activity in the absence of signal 1, suggesting that REGN17372 may not be associated with characteristic oral, skin, and nail toxicities observed with GPRC5D×CD3 bispecific antibodies. Additionally, unlike agonistic CD28 monoclonal antibodies, REGN17372 did not directly induce nuclear factor of activated T cells signaling or cytokine production in MM cells co-expressing CD28 and GPRC5D.
Building on these promising preclinical results, a Phase 1 clinical trial is underway to evaluate the safety, tolerability, and preliminary efficacy of REGN17372 combined with linvoseltamab in patients with RRMM. This innovative approach, leveraging the combinatorial potential of GPRC5D×CD28 costimulation with the targeted cytolytic activity of linvoseltamab, represents a novel therapeutic strategy that could significantly improve outcomes for patients with MM.
DISCLOSURES
David J. DiLillo, PhD: Regeneron Pharmaceuticals, Inc. - Current equity holder in publicly-traded company; Regeneron Pharmaceuticals, Inc. - Stock (publicly traded); Regeneron Pharmaceuticals, Inc. - Current Employment